New US approval sought for Darzalex Faspro quadruple therapy
Johnson & Johnson (J&J) is seeking U.S. Food and Drug Administration (FDA) approval for a quadruple treatment regimen based on Darzalex Faspro (daratumumab and hyaluronidase-fihj) for adults with newly diagnosed multiple myeloma for whom a stem cell transplant was not initially planned. The quadruple regimen combines Darzalex…